



Novel Proteins and Nucleic Acids Encoding Same

RELATED APPLICATIONS

5

This is a request for filing a new nonprovisional application under 37 C.F.R. §1.53(b).

This application claims priority to U.S.S.N. 60/274,322 filed on March 8, 2001 (Cura 590); U.S.S.N. 60/283,675 filed on April 13, 2001 (Cura 590D1); U.S.S.N. 60/338,092 filed on December 3, 2001 (Cura 590D2); U.S.S.N. 60/274,281 filed on March 8, 2001

- 10 (Cura 591); U.S.S.N. 60/274,1[0]91 filed on March 8, 2001 (Cura 592); U.S.S.N. 60/325,681 filed on September 27, 2001 (Cura 592J1); U.S.S.N. 60/304,354 filed on July 10, 2001 (Cura 592I1); U.S.S.N. 60/279,995 filed on March 30, 2001 (Cura 592H1); U.S.S.N. 60/294,899 filed on May 31, 2001 (Cura 592E1); U.S.S.N. 60/287,424 filed on April 30, 2001 (Cura 592D1); U.S.S.N. 60/299,027 filed on June 18, 2001 (Cura 592D2);
- 15 U.S.S.N. 60/309,198 filed on July 31, 2001 (Cura 592C1); U.S.S.N. 60/281,[19]444 filed on April 4, 2001 (Cura 592A1); U.S.S.N. 60/274,194 filed on March 8, 2001 (Cura 593); U.S.S.N. 60/274,849 filed on March 9, 2001 (Cura 594); U.S.S.N. 60/330,380 filed on October 18, 2001 (Cura 594C1); U.S.S.N. 60/275,235 filed on March 12, 2001 (Cura 595); U.S.S.N. 60/288,342 filed on May 3, 2001 (Cura 595J1); U.S.S.N. 60/275,578 filed
- 20 on March 13, 2001 (Cura 596); U.S.S.N. 60/291,240 filed on May 16, 2001 (Cura 596I1); U.S.S.N. 60/294,485 filed on May 30, 2001 (Cura 596B1); U.S.S.N. 60/299,310 filed on June 19, 2001 (Cura 596A1); U.S.S.N. 60/275,579 filed on March 13, 2001 (Cura 597); U.S.S.N. 60/275,601 filed on March 13, 2001 (Cura 598); U.S.S.N. 60/276,000 filed on March 14, 2001 (Cura 599); U.S.S.N. 60/280,900 filed on April 2, 2001 (Cura 599E1);
- 25 U.S.S.N. 60/276,776 filed on March 16, 2001 (Cura 600); U.S.S.N. 60/294,889 filed on May 31, 2001 (Cura 600G1); U.S.S.N. 60/318,770 filed on September 12, 2001 (Cura 600E1); U.S.S.N. 60/276,994 filed on March 19, 2001 (Cura 604); U.S.S.N. 60/277,338 filed on March 20, 2001 (Cura 607); U.S.S.N. 60/325,430 filed on September 27, 2001 (Cura 607J1); U.S.S.N. 60/332,094 filed on November 21, 2001 (Cura 607C1); U.S.S.N.
- 30 60/299,303 filed on June 19, 2001 (Cura 607B1); U.S.S.N. 60/288,066 filed on May 2, 2001 (Cura 607A1); U.S.S.N. 60/277,321 filed on March 20, 2001 (Cura 608); U.S.S.N. 60/280,822 filed on April 2, 2001 (Cura 608A); U.S.S.N. 60/277,239 filed on March 20, 2001 (Cura 609); U.S.S.N. 60/277,327 filed on March 20, 2001 (Cura 610); U.S.S.N.

Version With Markings To Show Change

60/277,791 filed on March 21, 2001 (Cura 611); U.S.S.N. 60/333,184 filed on November 14, 2001 (Cura 611H1); U.S.S.N. 60/277,833 filed on March 22, 2001 (Cura 612); U.S.S.N. 60/318,462 filed on September 10, 2001 (Cura 612J1); U.S.S.N. 60/288,528 filed on May 3, 2001 (Cura 612A1); U.S.S.N. 60/278,152 filed on March 23, 2001 (Cura 613); U.S.S.N. 60/332,272 filed on November 14, 2001 (Cura 613D1); U.S.S.N. 60/278,894 filed on March 26, 2001 (Cura 614); U.S.S.N. 60/312,903 filed on August 16, 2001 (Cura 614C1); U.S.S.N. 60/333,272 filed on November 14, 2001 (Cura 614C2); U.S.S.N. 60/279,036 filed on March 27, 2001 (Cura 615); U.S.S.N. 60/332,172 filed on November 14, 2001 (Cura 615I1); U.S.S.N. 60/337,426 filed on December 3, 2001 (Cura 615I2); U.S.S.N. 60/278,999 filed on March 27, 2001 (Cura 616); U.S.S.N. 60/279,344 filed on March 28, 2001 (Cura 617); U.S.S.N. 60/332,271 filed on November 14, 2001 (Cura 617J1); U.S.S.N. 60/291,099 filed on May 16, 2001 (Cura 617H1); U.S.S.N. 60/291,190 filed on May 15, 2001 (Cura 617E1); U.S.S.N. 60/280,233 filed on March 30, 2001 (Cura 618); U.S.S.N. 60/280,802 filed on April 2, 2001 (Cura 621); U.S.S.N. 60/335,301 filed on October 31, 2001 (Cura 621F1); U.S.S.N. 60/337,185 filed on December 4, 2001 (Cura 621D1); and U.S.S.N. 60/345,705 filed on January 3, 2002 (Cura 621B1).

Field of the Invention

The present invention relates to novel polypeptides that are targets of small molecule drugs and that have properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions. The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them with various diseases or pathologies. The proteins and related proteins that are similar to them, are encoded by a cDNA and/or by genomic DNA. The proteins, polypeptides and their cognate nucleic acids were identified by Curagen Corporation in certain cases. The XYZase-encoded protein and

CONCLUSION

Applicants respectfully submit that the present application complies with 37 C.F.R. § 1.16(l) and §§ 1.821-1.825. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Eric Sinn, Reg. No. 40,177

Attorneys for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 13, 2002

NYC 250268v1



30623

PATENT TRADEMARK OFFICE